435 related articles for article (PubMed ID: 26852185)
1. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
[TBL] [Abstract][Full Text] [Related]
2. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease.
Abenavoli L; Larussa T; Corea A; Procopio AC; Boccuto L; Dallio M; Federico A; Luzza F
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33546130
[TBL] [Abstract][Full Text] [Related]
3. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
4. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Cicero AFG; Colletti A; Bellentani S
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
[TBL] [Abstract][Full Text] [Related]
5. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
6. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
7. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
[TBL] [Abstract][Full Text] [Related]
8. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.
Sangineto M; Bukke VN; Bellanti F; Tamborra R; Moola A; Duda L; Villani R; Romano AD; Serviddio G
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33671262
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation.
Micheli L; Pacini A; Di Cesare Mannelli L; Trallori E; D'Ambrosio R; Bianchini C; Lampertico P; Ghelardini C
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32570937
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28906453
[TBL] [Abstract][Full Text] [Related]
11. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J; Fernández-Galilea M; Martínez-Fernández L; González-Muniesa P; Pérez-Chávez A; Martínez JA; Moreno-Aliaga MJ
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31003450
[TBL] [Abstract][Full Text] [Related]
12. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.
Ni Y; Zhuge F; Nagashimada M; Ota T
Nutrients; 2016 Jun; 8(7):. PubMed ID: 27347998
[TBL] [Abstract][Full Text] [Related]
13. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
Salomone F; Godos J; Zelber-Sagi S
Liver Int; 2016 Jan; 36(1):5-20. PubMed ID: 26436447
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Azzalini L; Orando S; Orlando R; Angelico F
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004996. PubMed ID: 17253535
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
Vadarlis A; Antza C; Bakaloudi DR; Doundoulakis I; Kalopitas G; Samara M; Dardavessis T; Maris T; Chourdakis M
J Gastroenterol Hepatol; 2021 Feb; 36(2):311-319. PubMed ID: 32810309
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
Chen LH; Wang YF; Xu QH; Chen SS
Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
[TBL] [Abstract][Full Text] [Related]
20. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.
Abenavoli L; Greco M; Milic N; Accattato F; Foti D; Gulletta E; Luzza F
Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
